Mesoblast (NASDAQ: MESO) details ASX equity changes in 6-K filing update

Rhea-AI Filing Summary

Mesoblast Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish investors with copies of two equity-related announcements it filed with the Australian Securities Exchange on January 15, 2026. One attached exhibit is an Appendix 3H covering a cessation of securities, and the other is an Appendix 3G relating to the issue, conversion or payment up of unquoted equity securities. These ASX appendices are included as Exhibits 99.1 and 99.2 so U.S. investors can access the same equity capital changes information filed in Australia.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of January 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On January 15, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, notification of cessation of securities (Appendix 3H) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On January 15, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, notification of issue, conversion or payment up of unquoted equity securities (Appendix 3G) which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: January 16, 2026

INDEX TO EXHIBITS

Item
99.1						Appendix 3H of Mesoblast Ltd, dated January 15, 2026.
99.2						Appendix 3G of Mesoblast Ltd, dated January 15, 2026.

FAQ

What does Mesoblast (MESO) report in this Form 6-K?

Mesoblast Limited reports that it has filed two equity-related announcements with the Australian Securities Exchange on January 15, 2026, and furnishes them as exhibits to this Form 6-K.

What are the ASX documents attached to Mesoblasts Form 6-K?

The Form 6-K attaches Appendix 3H, a notification of cessation of securities, as Exhibit 99.1, and Appendix 3G, a notification of issue, conversion or payment up of unquoted equity securities, as Exhibit 99.2.

Why did Mesoblast (MESO) file Appendix 3H with ASX?

Appendix 3H is described as a new issue announcement and notification of cessation of securities, indicating that Mesoblast notified ASX about securities that have ceased, with the details contained in Exhibit 99.1.

What is the purpose of Mesoblasts Appendix 3G filing?

Appendix 3G is a new issue announcement and notification of issue, conversion or payment up of unquoted equity securities, with the specifics provided in Exhibit 99.2 attached to the Form 6-K.

Does this Mesoblast Form 6-K include the full terms of the equity changes?

The Form 6-K itself mainly identifies and incorporates by reference the ASX Appendices 3H and 3G; the detailed terms of the equity changes are contained within those exhibits.